Figure (Figure001)
This text provides information on the results of a study called MERIT-HF, focusing on the total mortality and hospitalization outcomes for heart failure patients treated with Wetoprolol Succinate Extended-Release tablets compared to a placebo. The study looked at various subgroups including NYHA class, ejection fraction, ischemic etiology, sex, race, previous medical history such as myocardial infarction, diabetes, and hypertension. It also includes mean heart rates for different subgroups. The study indicates favorable outcomes for Wetoprolol Succinate in certain subgroups. Key terms include US (United States), NYHA (New York Heart Association), EF (ejection fraction), and HR (heart rate).*